CRISPR Generation Call 2026

The NIHR Great Ormond Street Hospital Biomedical Research Centre (GOSH BRC) is a partnership between Great Ormond Street Hospital and the University College London (UCL) Great Ormond Street Institute of Child Health (ICH). The NIHR GOSH BRC provides cutting-edge facilities and world-leading expertise and access to over 200 rare disease patient populations allowing our staff and NHS, university, and industry collaborators to conduct pioneering translational research into childhood illnesses. GOSH and UCL ICH were first awarded BRC status by the NIHR in 2007 and, in July 2022, we secured £35 million for our fourth term from 2022 – 2028. Essential to delivering the BRC’s strategy is also our newly created Paediatric Excellence Initiative (PEI), a partnership between the GOSH BRC, Alder Hey, Birmingham and Sheffield Children’s Hospitals. The GOSH BRC operates across five research themes, including the Accelerating Novel Therapies (ANT) theme, which supports the CRISPR Service. The ANT theme develops treatment for rare diseases through early bench-to-bedside translation, innovative trial methodologies, and biomarker development.

Led by our CRISPR Research Fellow Dr Shalini Kamu Reddy, the NIHR GOSH BRC supports research projects across the ANT theme and the wider BRC and research community by providing discounted access to CRISPR gene-editing services to accelerate the development of disease models and translational studies.

We are inviting GOSH, GOS-ICH, UCL, our PEI investigators, and external collaborators* to submit applications requesting support to enable the generation of CRISPR lines for disease modelling or CRISPR-based screening projects.

*External collaborators must apply jointly in partnership with a lead applicant whose substantive employer is GOSH, GOS-ICH, UCL or a PEI partner organization. For this project, the internal applicant needs to sign off on the terms of reference for the project.

• The applications must be within the remit of the GOSH BRC, i.e., supporting translational research focused on paediatric rare or complex disease.
• Applicants/Collaborators must have an existing employment contract with GOSH or GOS-ICH or our PEI partners when they apply, which must be in place for the duration of the award.
• This service is supported by NIHR funding and is formally not allowed to support any research using animals; therefore, any project supported through this call must not involve animal work.
• Awardees must acknowledge the NIHR GOSH BRC in any publications and presentations and produce progress reports to the BRC upon request (including one year after the project end date).

The NIHR GOSH BRC provides discounted CRISPR line generation to support translational paediatric research. Pricing reflects the scope and complexity of the requested edit.

Project Pricing

• Knockout, standard indel to large deletion: £3,000 to £5,000 per project
• Knock in, single SNP to large insertion: £4,000 to £6,000 per project
• Compound heterozygote or dual locus editing models: £5,000 to £7,000 per project

Final pricing will be confirmed following technical feasibility assessment prior to project initiation. These fees ensure access to high-quality genome-editing expertise and facilities. Please refer to the CRISPR Services Terms and Conditions (Page 7 of the Guidelines and Application Form) for full details on pricing structure, refunds, VAT, and service scope.

You do not need to have had prior links with the GOSH BRC to be eligible to apply. If you would like to apply, please read and complete the APPLICATION FORM and return as a word document to brc@gosh.nhs.uk

• Applications will be reviewed by the BRC Accelerating Novel Therapies Leadership Team and the CRISPR Service Lead
• To apply please complete the application form and submit an electronic copy as a word document to brc@gosh.nhs.uk

Please contact brc@gosh.nhs.uk if you have any questions about the CRISPR service.